New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
09:02 EDTENDP, BDSIBioDelivery Sciences could be bought by Endo, says Summer Street
Summer Street sees shares of BioDelivery Sciences (BDSI) heading to the $15 level on positive buprenorphine data in July, a drug the company partners with Endo (ENDP). The firm notes Endo could owe up to $70M in milestones to BioDelivery, but it finds it more likely that Endo buys BioDelivery outright. Summer Street keeps a Buy rating on the stock with a $20 price target.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:57 EDTENDPPerrigo confirms first to file patent challenge for generic version of Aveed
Subscribe for More Information
07:11 EDTENDPTrimel announces license agreement with Endo for NATESTO
Subscribe for More Information
07:02 EDTENDPEndo acquires rights to Natesto testosterone nasal gel
Endo announced the acquisition of rights to Natesto, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporatio. Natesto™ was approved by the FDA in May of 2014. Under the terms of the agreement Trimel will receive an upfront payment of $25M and could receive additional payments upon the achievement of certain regulatory and sales milestones. Additionally, Trimel will be responsible for the manufacture and supply of Natesto and Endo will pay a tiered supply price for the product. Endo expects the transaction to close in early 2015. Under the terms of the agreement, Endo receives sole and exclusive commercial rights to the Natesto product in the US and Mexico. In addition, Endo will collaborate on all regulatory and clinical development activities in coordination with Trimel.
November 21, 2014
14:51 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information
November 20, 2014
07:33 EDTENDPEndo launches generic version of Hoffmann-La Roche's Valcyte
Endo's Qualitest subsidiary has launched a generic version of Hoffmann-La Roche's Valcyte. For the 12 months ending September 30, Valcyte had total U.S. sales of approximately $440M, according to IMS Health data.
November 19, 2014
10:21 EDTENDPHigh option volume stocks
Subscribe for More Information
07:33 EDTENDPEndo, Auxilium receive early termination of HSR waiting period for deal
Subscribe for More Information
07:09 EDTBDSIJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 14, 2014
09:38 EDTENDPJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use